Investor Presentaiton slide image

Investor Presentaiton

The Biocon Journey: A Continuous Evolution THE An 1978- 1999 Enzymes Company 2005- 2010- 2016- 2019 & 00-000 2000- 2004 Transforming into a Biopharma Company Successful IPO, Biocon listed in India (2004) 2009 Building the Base Business and Expertise in Biologics Enzymes Business Divested (2007) Global 2015 Strategic Global Alliance with Mylan for Biosimilars Expanded (2013) Generic Formulations Development of Biosimilars in Partnership with Mylan (2009) Business Unit set up (2013) IPO of Syngene (2015) 2018 Commercialized Biosimilars for Diabetes & Cancer in Japan, U.S., EU Global Partnership with Sandoz for Next- Gen Biosimilars (2018) Beyond Poised for Global Impact with Biosimilars Investments in complex Generic Formulations $ Biocon Touching a billion lives through affordable innovation Unwavering focus through the years on innovation & difficult to make, niche products to create tangible differentiators for sustainable growth 5
View entire presentation